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Patient selection affects end-stage renal disease outcome com- known that important geographic differences in end-
parisons. Geographic differences in dialysis patient outcome stage renal disease (ESRD) survival exist, with US hemo-
could be partially explained by demographic and baseline com- dialysis patients having a higher risk of death than thoseorbid characteristics, including cardiovascular disease. To eval-
treated in Japan and in Europe [2]. However, registryuate the influence of patient selection on outcome comparisons,
data should be used with caution when comparing dial-we focus on the effect of cardiovascular disease on ESRD
patient outcome using data from the Lombardy Registry. A ysis patient survival because they may be affected by
total of 4139 ESRD patients (aged 61.9 6 15.6 years, males several, sometimes hidden, factors. Indeed, country dif-
60.5%, diabetics 20%) who started renal replacement therapy ferences may include characteristics of the general popu-(RRT) between 1994 and 1997 were considered. The analysis
lation (life expectancy, prevalence of diabetes and car-of 4-year survival in the presence or absence of ischemic heart
diovascular diseases), the acceptance rate of uremicdisease and congestive heart failure at the beginning of RRT
was performed using cardiovascular mortality and mortality patients (the higher the acceptance rate, the higher the
from any cause as endpoints. Survival was compared by means possibility of treating patients with several concomitant
of the Cox regression proportional hazard model; explanatory risk factors at the start of RRT), gender and age distribu-covariates were age, gender and diabetic status. Of the patients
tion, baseline comorbid conditions, withdrawal rate dueconsidered for the study, 918 (22.2%) died during the 4-year
to kidney transplant, and treatment modalities (hemodi-follow-up; the main cause of death was cardiovascular disease
(cardiac causes in 304 patients [33.1%], vascular causes in 88 alysis/peritoneal dialysis) [3]. As the American National
patients [9.6%.]). Patients with ischemic heart disease at the Cooperative Dialysis Study (NCDS) first demonstrated
beginning of RRT had significantly higher mortality from myo- [4], patient morbidity and treatment failure were greatlycardial infarction or from any cause than those without. The
related to inadequate dialysis doses. However, the conse-mortality risk for myocardial infarction was higher for elderly
quent progressive increase in the mean dialytic dose and(RR 5 1.04 per year; P 5 0.0001) and diabetic patients (RR 5
2.19; P 5 0.0006). Chronic heart failure strongly affected overall duration that has been obtained in the last decade in
mortality but not that from myocardial infarction. Ischemic the United States seems to have only slightly reduced
heart disease and chronic heart failure are very common in mortality [5]. This suggests that increasing age and aincident ESRD patients and their presence is an important
greater proportion of ESRD patients with complex medi-determinant of survival. Particular interventions are needed to
cal comorbidity largely contribute to the lower survivalprevent the development of cardiac abnormalities starting as
early as possible during the predialytic phase. in the United States. Age is certainly the most important
demographic factor associated with increased mortality,
together with the increasing incidence of ESRD diabetic
The major clinical problems currently facing dialysis patients. Malnutrition and anemia also contribute to
management are connected to the high level of morbidity higher mortality in RRT. The high prevalence of cardio-
and mortality. As in the case of many chronic medical vascular disease among dialysis patients is of particular
conditions, the life expectancy of patients undergoing concern, since this pathology accounts for more than
renal replacement therapy (RRT) is greatly reduced (20– 50% of mortality in these patients, at an approximately
25% that of the general population [1]). It is also well 30 times higher rate than in the general population [6].
The incidence of cardiovascular disease is not only high
in diabetic primary hypertensive patients, but also among1 See Appendix for list of participating researchers and centers.
those with chronic glomerulonephritis, thus leading to
Key words: cardiovascular disease, congestive heart failure, dialysis. the definition of chronic renal failure as a “vasculopathic
state” [7]. 2000 by the International Society of Nephrology
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The prevalence of the clinical manifestations of cardio- cember 31, 1997). Evaluating mortality from myocardial
infarction, the patient’s death from any other cause werevascular disease and echocardiographic abnormalities is
already high at the beginning of RRT [8], and cardiac considered censors. In order to avoid the inclusion of
“acute” patients, those patients who reached the endabnormalities are all independent predictors of both
overall and cardiac mortality (more than two-thirds of point or who were censored during the first 30 days of
treatment, were excluded from the analysis. Thus, pa-dialysis patients with left ventricular hypertrophy [LVH]
die from heart failure or sudden death [6, 9]). Further- tient follow up ranged between 1 and 48 months.
Cox proportional hazard regression models [12] weremore, the long-term survival of hemodialysis patients
experiencing acute myocardial infarction is disappointing used to evaluate the effect of the presence of ischemic
heart disease and CHF on mortality from myocardialwhen compared with that of the general population [10].
Given the detrimental impact of these complex comor- infarction and mortality from any cause, after having
adjusted for age, gender and diabetic status. Ischemicbid conditions on dialysis patient quality of life and sur-
vival, their adequate assessment is extremely important heart disease at the beginning of RRT was defined as a
single covariate with two levels of severity (i.e., CADnot only in comparing outcomes in different dialysis pop-
ulations, but also in possibly evaluating the effects of risk and myocardial infarction). The patients were censored
as for the descriptive analysis.factor reduction and of other therapeutic interventions.
Aim of the present study was to assess the influence All the statistical analyses were made using the SPSS
version 7.5 (SPSS, Inc., Chicago, IL, USA) softwareof patient selection on outcome comparisons, focusing
on the magnitude of the effect of cardiovascular risk package. The contribution of the covariates to explain
the dependent variable was assessed by means of a two-factors and of the presence of cardiac disease (i.e., ische-
mic heart disease and congestive heart failure [CHF]) tailed likelihood ratio test, with P-values , 0.05 being
considered significant.at the beginning of RRT on ESRD patient outcome.
METHODS RESULTS
Patient characteristicsPatients and data collection
The data used in this analysis came from the Dialysis The mean age (6 SD) of the patients admitted to
RRT was 61.9 6 15.6 years, ranging from 60.1 6 15.4 inand Transplant Lombardy Registry (RLDT), and in-
cluded 4139 patients who started RRT for ESRD be- 1994 to 62.5 6 15.4 in 1997. There was an excess of
male patients (males 5 60.5%), which was without anytween January 1, 1994, and December 31, 1997 in the
44 Lombardy dialysis units. The Registry was begun in significant change from 1994 to 1997. At the beginning
of RRT, CAD and myocardial infarction were present in,1982 under the aegis of the Lombardy Regional Section
of the Italian Society of Nephrology and the Regional respectively, 415 (10.0%) and 343 (8.3%) of the patients
(total ischemic heart disease equal to 18.3%); CHF wasHealth Department. Data were collected at the end of
each year (100% center response rate). A detailed study present in 367 of the patients (8.9%). The percentage
of incident ESRD patients with CAD or documentedconcerning the 1983–1992 dialysis and transplantation
results in Lombardy has been published previously [11]. myocardial infarction at the beginning of RRT remained
relatively stable during the four-year follow-up periodPatients having cardiovascular disease were defined
as follows, according to the instructions of RLDT to (from 9.5% to 9.9% and from 8.4% to 8.6%, respec-
tively), whereas the percentage of patients with CHFdialysis centers: 1) coronary artery disease (CAD): clini-
cal or instrumental evidence of coronary artery disease progressively increased (from 5.4 to 10.6%). The propor-
tion of new patients with diabetes (both type 1 and typeincluding coronary bypass, angioplasty; 2) myocardial
infarction: documented myocardial infarction; 3) CHF: 2) as a comorbid risk factor was 20.0% (from 18% to
24%), whereas the percentage of new ESRD patientsabnormality of cardiac function responsible for failure
to pump at a rate commensurate with the requirements with diabetic nephropathy as primary renal disease was
11.9% in 1994 and increased to 17.1% in 1997.of the metabolizing tissues, by clinical or instrumental
evaluation.
Patient survival
Statistical methods Nine hundred eighteen (22.2%) patients died during
the four-year period, with a death rate of 13.6 per 100The univariate descriptive analysis of survival were
performed by the KaplanMeier technique, using mortal- patient-years. Similarly to other Western countries, car-
diovascular disease was the main cause of mortality, ac-ity from myocardial infarction and mortality from any
cause as end points. Evaluating general mortality, pa- counting for nearly 43% of the deaths (cardiac causes
in 304 patients [33.1%] and vascular causes in 88 patientstients were censored when transferred to a dialysis unit
out of Lombardy and at the final observation date (De- [9.6%]). Cachexia was the second cause of death (N 5
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Table 1. Relative risk rates for death from myocardial infarction
by demographic and comorbid factors referring to the beginning
of RRT according to Cox’s main effect model
95% CI
Covariate RR Lower Upper P
Age (per year) 1.04 1.02 1.06 0.0001
Gender (ref: F) 1.16 0.73 1.83 NS
Diabetes 2.19 1.4 3.42 0.0006
CHF 1.16 0.64 2.11 NS
CAD 2.88 1.63 5.08 0.0003
MI 5.94 3.55 9.95 ,0.0001
Abbreviations are: CHF, congestive heart failure; CAD, coronary artery dis-
ease; MI, myocardial infarction.
Fig. 2. Survival from myocardial infarction according to the presence
of ischemic heart disease (CAD or myocardial infarction) at the begin-
ning of RRT in the 1994–97 incident ESRD patients of the Lombardy
Registry after adjusting for age, gender, diabetic status and other vascu-
lar diseases.
Fig. 1. Survival from myocardial infarction according to the presence
of ischemic heart disease (CAD or myocardial infarction) at the begin-
ning of RRT in the 1994–1997 incident ESRD patients of the Lombardy
Registry, unadjusted.
Fig. 3. Overall survival according to the presence of CHF at the begin-
ning of RRT in the 1994–97 incident ESRD patients of the Lombardy167, 18.2%), followed by malignancies (N 5 105, 11.4%),
Registry.
infections (N 5 93, 10.1%), gastrointestinal disease (N 5
42, 4.6%), liver disease (N 5 14, 1.5%) and social/psycho-
logical causes (N 5 12, 1.3%). Miscellaneous causes ac-
counted for the 10.1% of the deaths (N 5 93). spectively, in the presence of CAD or myocardial in-
farction. After adjusting for age, gender, diabetic status,The cumulative survival of all the ESRD patients was
of 86.3%, 76.4% and 67.2% after 1, 2 and 3 years of and other vascular diseases, the relative death rate from
myocardial infarction was still significantly higher in thefollow-up, respectively.
The results based on the Cox proportional hazard presence of CAD (RR 5 2.88, 95% confidence interval
[1.40–3.42], P 5 0.0003) or myocardial infarction (RR 5model concerning mortality from myocardial infarction
are given in Table 1. The mortality risk from myocardial 5.94, 95% confidence interval [3.55–9.95], P , 0.001)
(Fig. 2).infarction was higher for older patients (RR 5 1.04 per
year older; P 5 0.0001). Compared with non-diabetics, The presence of CHF at the beginning of RRT did
not influence mortality from myocardial infarction, butthe death rate from myocardial infarction of patients
with diabetes as a comorbid condition was 2.19 higher it strongly affected overall survival. The patients with
this condition had markedly reduced 4-year survival that(P 5 0.0006). Gender did not significantly affect survival.
As far as the role of ischemic heart disease is concerned, was significantly lower than that of the patients without
(about 20% and 60%, respectively; P , 0.05) (Fig. 3).the results are presented in Figs. 1 and 2. Figure 1 shows a
statistically significant higher mortality from myocardial The adjusted death rate for the patients with CHF was
64% greater than that of the patients without (RR 5infarction in patients with ischemic heart disease at the
beginning of RRT, with a cumulative survival of about 1.64, 95% confidence interval 1.36–1.98, P , 0.0001).
Ischemic heart disease at the beginning of RRT also98% after 48 months of follow-up in the absence of
ischemic heart disease and of about 89% and 81%, re- largely affected mortality from any cause. At 48 months,
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Table 2. Relative risk rates for death from any cause by
demographic and comorbid factors referring to the beginning of
RRT according to Cox’s main effect model
95% CI
Covariate RR Lower Upper P
Age (per year) 1.06 1.05 1.06 ,0.0001
Gender (ref: F) 1.04 0.91 1.19 NS
Diabetes 1.37 1.18 1.59 ,0.0001
CAD 1.15 0.95 1.38 NS
MI 1.32 1.07 1.61 0.009
CHF 1.64 1.36 1.98 ,0.0001
Abbreviations are: CHF, congestive heart failure; CAD, coronary artery dis-
ease; MI, myocardial infarction
Fig. 4. Overall survival according to the presence of ischemic heart
disease (CAD or myocardial infarction) at the beginning of RRT in
the 1994–97 incident ESRD patients of the Lombardy Registry. ease is partially due to a higher prevalence of conditions
which are recognized as risk factors for cardiovascular
disease in the general population, such as older age,
hypertension, hyperlipidemia, diabetes, tobacco use,
physical inactivity [6]. In addition, uremia itself provides
a number of hemodynamic and metabolic perturbations
that favor atheroma and clot formation and vascular-
wall damage. Together with anemia, inadequate salt and
water removal and consequent hypertension are also
important determinants. For this reason, Kt/V has no
longer been assumed to be the only means of estimating
dialysis adequacy, and increasing importance has been
given to treatment time in relation to an additional aspect
of dialysis adequacy: achieving dry body weight and thus
normalizing blood pressure. However, the awareness ofFig. 5. Overall survival according to the presence of ischemic heart
disease (CAD or myocardial infarction) at the beginning of RRT in the importance of dialysis adequacy has only partially
the 1994–97 incident ESRD patients of the Lombardy Registry after improved survival in ESRD patients, who still have an
adjusting for age, gender, diabetic status and other vascular diseases.
extremely low life expectancy.
The results of our large epidemiological study confirm
that cardiac disease is a very common condition in the
the patients with CAD or myocardial infarction had sig-
incident ESRD patients at the beginning of RRT. Thisnificantly lower survival (about 38% and 40%, respec-
may be partially influenced by the fact that Lombardytively) compared with that of the patients without (about
has one of the highest acceptance rate of ESRD patients65%) (Fig. 4). After adjusting for age, gender, diabetic
to RRT among European countries [11]. Indeed, higherstatus and other vascular diseases, mortality was still
acceptance rates increase the likelihood of treating pa-significantly higher in the presence of myocardial in-
tients with several concomitant risk factors that are morefarction at the beginning of RRT (RR 5 1.32, 95% con-
likely at risk of death. Increasing age and a greater pro-fidence interval 1.07–1.61) (Fig. 5). However, the ad-
portion of ESRD patients with diabetes and complexjusted death rate for the patients with CAD at the
medical comorbidity largely contribute to increased mor-beginning of RRT was not statistically different from
that of the patients without (RR 5 1.15, 95% confidence tality. The elderly are frailer and intercurrent medical
interval 0.95–1.38). Table 2 shows the results based on conditions are more likely to occur with advancing age.
the Cox proportional hazard model concerning mortality Furthermore, vascular disease and diabetes are the most
from any cause. Age, diabetic status, congestive heart frequent causes of ESRD in elderly patients, thus further
failure and myocardial infarction all independently af- increasing the risk of cardiovascular death.
fected survival (RR of 1.06, 1.37, 1.64, 1.32, respectively), Age of incident patients is continuously increasing in
whereas CAD and gender did not. Lombardy: from 1994 to 1997 the proportion of patients
older than 64 years increased from 44.6% to 53.5%.
DISCUSSION Selecting the patients without cardiovascular disease at
the acceptance on dialysis treatment, the risk to developCardiovascular disease is the major cause of death in
ESRD patients. The excess risk for cardiovascular dis- de novo cardiovascular disease increases by 4% for each
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year of age (RR 5 1.04, 95% confidence interval 1.02– around, it is likely that LVH predisposes to the develop-
ment of ischemic symptoms [19]. Unfortunately, data1.04, P , 0.001).
The proportion of ESRD patients affected by diabetes were not available concerning the impact of LVH in our
population.(considering not only the patients with diabetic nephrop-
athy as primary renal disease, but all the patients with It should be considered that the ability to maintain
extracellular volume with ultrafiltration may obscure thea diabetic status) who were accepted on dialysis in Lom-
bardy from 1994 to 1997 also greatly increased (from diagnosis of CHF and hypotension either before or dur-
ing the dialysis procedure may be the only manifestation18.5% to 24.1%). It is well known that survival of ESRD
diabetics is shorter than that of diabetics in the general of cardiac failure. Indeed, the already mentioned Cana-
dian multicenter study found that low mean arterialpopulation [13] and that of their nondiabetic ESRD coun-
terparts, about half of the excess mortality being attribut- blood pressure was independently associated with mor-
tality (RR 1.36 per 10 mmHg fall, P 5 0.009), probablyable to cardiovascular causes [14, 15]. As expected, in
our population the diabetics without documented cardio- reflecting the fact that cardiac failure occurred prior to
death, as a consequence of cardiac hypertrophy or dila-vascular disease at baseline had a higher age-adjusted
risk of developing cardiovascular disease thereafter tion [21]. Unfortunately, the Lombardy Registry is not
able to collect data concerning interdialytic weight gains(RR 5 1.56, confidence interval 1.19–2.05, P 5 0.043).
As in the general population, ischemic heart disease and blood pressure values. Thus, it is not possible to
completely exclude either an overestimation of the prev-was an independent predictor of death from myocardial
infarction in the dialysis patients of the Lombardy Regis- alence of CHF because of fluid overload or, on the
other side around, an underestimation in the patients intry. The relative risk of death due to this disease was
higher when a myocardial infarction had already oc- whom the presence of hypotension was the only symp-
tom of CHF.curred than in the presence of only a certain degree of
CAD or in the absence of cardiac disease. Perhaps pa- In conclusion, the results of our epidemiological study
tients who experienced an acute myocardial infarction of a large number of dialysis patients confirm that cardio-
had more severe coronary stenosis and thus were at vascular disease is the main factor affecting morbidity
increased risk of rapidly exhausting the coronary vasodi- and mortality. Particular interventions are therefore
lator reserve, even in the presence of minimal increases needed to prevent the development of cardiac abnormal-
in myocardial oxygen requirement. However, the degree ities in this population. In particular, the correction of
of atherosclerotic coronary arterial narrowing often does anemia, an adequate antihypertensive treatment, and the
not predict the risk of thrombotic occlusion [16, 17]. limitation of saline and volume overload are crucial.
Heart failure was not an independent predictor of Given that patients starting RRT generally have such
cardiovascular death in our study. This is probably ex- badly damaged hearts that they have reached not only
plained by the fact that CHF is caused by a number ESRD but also “near-terminal cardiac failure” [22],
factors (such as volume overload, anemia, hypertension, these interventions should be started as early as possible
arteriovenous fistula, uremia-related myocardial cell in- in the predialytic phase. A more intensive approach to
jury) besides ischemic heart disease that do not directly diagnosis and treatment of cardiovascular disease may
influence the development of CAD. also improve outcomes in ESRD patients [23].
On the other hand, both symptomatic heart failure
and ischemic heart disease negatively affected overall
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